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Purpose: The aim of this study was to evaluate and compare the long-term clinical 
outcomes of the spot drug-eluting stent (DES) implantation strategy, which is used to 
minimize implanted stent length and the number of stents, versus full lesion cover-
age for treatment of coronary artery stenoses. Materials and Methods: We evaluat-
ed 1-year clinical outcomes of 1619 patients with stent implantation for a single cor-
onary lesion. They were divided into two groups: those treated by full lesion 
coverage (n=1200) and those treated with the spot stenting strategy (n=419). The 
combined occurrence of 1-year target vessel failure (TVF), including cardiac death, 
target-vessel related myocardial infarction, or ischemia-driven target-vessel revascu-
larization was evaluated. Results: The spot DES implantation group had a shorter 
stent length (23.14±9.70 mm vs. 25.44±13.24 mm, respectively; p<0.001) and a 
fewer number of stents (1.09±0.30 vs. 1.16±0.41, respectively; p<0.001), even 
though the average lesion length was similar to the full lesion coverage group 
(21.36±10.30 mm vs. 20.58±10.97 mm, respectively; p=0.206). Spot DES implanta-
tion was superior to full DES coverage with respect to 1-year TVF (1.4% vs. 3.3%, 
p=0.044). Cox proportional hazard model analysis showed that the risk for 1-year 
TVF was almost 60% lower among patients who received spot DESs compared to 
those who received full DES coverage after adjustment for other risk factors 
(HR=0.40, 95% confidence interval=0.17-0.98; p=0.046). Conclusion: Minimizing 
stent length and the number of stents with overlapping by spot DES implantation 
may result in reduced rates of 1-year TVF, compared with full DES coverage.
Key Words:   Drug-eluting stents, percutaneous coronary intervention, coronary 
artery disease
INTRODUCTION
To reduce the occurrence of restenosis, a strategy of full lesion coverage is recom-
mended for percutaneous coronary intervention (PCI) of coronary lesions.1-3 The 
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tion (n=419). All study participants provided written, in-
formed consent using documents approved by the Institu-
tional Review Board at each participating center. 
All interventions were performed according to standard in-
terventional techniques. In the full DES coverage group, 
stents were deployed to cover the full length of the athero-
sclerotic lesion without residual stenosis in the reference seg-
ment by angiographic analysis. In the spot DES implantation 
group, selective stent implantation sites of hemodynamically 
significant portions of the lesions (defined as diameter steno-
sis >50%), as identified by angiographic analysis, were cho-
sen.4 Pre-PCI, all patients received at least 75 mg of aspirin. 
A loading dose of 300 mg clopidogrel was administered at 
least 12 hours pre-PCI. However, in cases when clopidogrel 
was not administered 12 hours in advance, the patient re-
ceived a 600 mg loading dose in the catheterization labora-
tory prior to PCI. Unfractionated heparin was administered 
to maintain the activated clotting time >250 seconds. The 
use of the glycoprotein IIb/IIIa inhibitors was left to the op-
erator’s discretion. After stent implantation, aspirin (100 
mg/day) was prescribed indefinitely, and the duration of 
clopidogrel (75 mg/day) depended on the randomization 
assignment: 3-month duration following E-ZES implanta-
tion vs.12-month duration following other DES implanta-
tion. The use of cilostazol was not allowed.
Quantitative coronary angiography analysis was performed 
using an off-line quantitative coronary angiographic system 
(CASS system, Pie Medical Instruments, Maastricht, the 
Netherlands) before and after stent implantation. Analysts 
in an independent core laboratory at the Cardiovascular Re-
search Center, Seoul, Korea were blinded to clinical infor-
mation. The stented segment plus 5-mm distal and proxi-
mal reference segments were selected for analysis. Using 
the guiding catheter for magnification-calibration, the diam-
eters of the reference vessel (the average of the proximal and 
distal reference lumen diameters), the minimal luminal diam-
eter, lesion length, and the percent diameter stenosis were 
measured before and after stenting from diastolic frames in a 
single, matched view showing the smallest minimal lumi-
nal diameter. Lesion length was defined as the distance 
from the proximal to the distal segment of the lesion site; 
that is between the segments with no stenosis evident in the 
projection assessed by angiogram.
Post-procedure clinical assessment was performed in-
hospital and 1, 3, 6, and 12 months after index procedure ei-
ther by a clinical visit or a telephone interview. Target vessel 
failure (TVF), defined as the combined occurrence of car-
use of longer or multiple stents could be an inevitable con-
sequence of spanning the full lesion between angiographi-
cally “healthy to healthy” segment.4 However, longer stent 
length has been indicated as an independent prognostic fac-
tor predicting adverse clinical outcomes with an increased 
rate of stent thrombosis and restenosis, even in the era of the 
drug-eluting stent (DES).5-7 To treat physically long coro-
nary lesions in the era of the bare-metal stent, intravascular 
ultrasound-guided balloon angioplasty with provisional 
spot stenting was suggested, and the angiographic and clini-
cal outcomes of this strategy were favorable compared to the 
matched control group treated with full lesion coverage.8 
Moreover, a recent randomized study examining the impact 
of length and multiple overlapping on DES effectiveness 
found favorable short- and long-term clinical outcomes in 
patients treated with spot DES implantation compared to 
those with full DES coverage in long coronary lesions.4 
However, data investigating the beneficial role of spot DES 
implantation are still insufficient. Particularly, the effect of 
this technique has not been systematically examined over all 
lesion lengths, including long lesions. Therefore, we exam-
ined the effect of spot DES implantation for treatment of not 
only long coronary lesions but all coronary lesions and com-
pared the long-term clinical outcomes between full DES cov-
erage and spot DES implantation in all DES-treated lesions. 
MATERIALS AND METHODS
　　　
The real safety and efficacy of 3-month dual antiplatelet ther-
apy (DAPT) following Endeavor zotarolimus-eluting stent 
(E-ZES; Medtronic, Inc., Santa Rosa, CA, USA) implanta-
tion trial (RESET trial) was a prospective, open label, ran-
domized trial conducted at 26 sites in Korea.9 The primary 
goal of this trial was to compare the safety and efficacy of 
two DES+DAPT implantation strategies: E-ZES+3-month 
DAPT versus standard therapy (other DES+12-month 
DAPT). Details regarding study design, inclusion and ex-
clusion criteria, and primary outcomes are provided in a 
prior publication.9 All participants were randomly assigned 
in a 1:1 ratio to receive either E-ZES+3-month DAPT (n= 
1059) or standard therapy (n=1058). Among 2117 patients, 
1619 patients treated with stent implantation for a single 
coronary lesion were selected for this study; multi-vessel and 
multi-lesion PCI were excluded. Selected patients were then 
divided into two groups according to treatment strategies; 
full lesion coverage (n=1200) versus spot DES implanta-
Seunghwan Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014586
ation, and categorical variables are expressed as number 
(%). Categorical variables were compared using χ2 statistics 
and Fisher’s exact test. Student’s t-test or the Mann-Whit-
ney U test was used to compare continuous variables. We 
estimated the cumulative event rate using the Kaplan-Meier 
method and calculated absolute differences and 95% confi-
dence intervals (CIs). The log-rank test was used to assess 
the significance of different incidences. A multivariable Cox 
proportional hazards model was used to evaluate the associ-
ation between the different stenting strategies (i.e., full DES 
coverage versus spot DES implantation) and TVF. The pro-
portional hazards assumption was evaluated for all variables 
by generating log-log survival plots for each predictor from 
the Cox regression model. Statistical analyses were per-
formed using the Statistical Package for the Social Sciences 
(version 18.0, SPSS Inc., Chicago, IL, USA). A p-value 
<0.05 was considered statistically significant.
 
RESULTS
 
Baseline clinical and angiographic characteristics of the two 
groups are shown in Table 1 and 2, respectively. Compared 
to the full DES coverage group, the spot DES implantation 
group had shorter stent length (25.44±13.24 mm vs. 23.14± 
9.70 mm, respectively; p<0.001) and fewer the number of 
stents (1.16±0.41 vs. 1.09±0.30, respectively; p<0.001), even 
diovascular death, target vessel-related myocardial infarc-
tion, or target vessel revascularization at one year post-pro-
cedure, was compared between the two groups. The patients 
were not scheduled for routine angiographic follow-up. 
Clinical events were defined according to the Academic 
Research Consortium.10 All deaths were considered cardio-
vascular deaths unless a definite non-cardiovascular cause 
was established. Myocardial infarction was defined as the 
presence of clinical symptoms, electrocardiographic chang-
es, or abnormal imaging findings of myocardial infarction. 
Findings were further substantiated with the presence of ei-
ther an increase in the creatine kinase myocardial band frac-
tion to greater than three times the upper limit of the normal 
range or an increase in troponin-T/troponin-I to more than 
the 99th percentile of the upper normal limit, unrelated to an 
interventional procedure.10 Target-vessel revascularization 
was defined as a repeat PCI or bypass surgery of the target 
vessel with either 1) ischemic symptoms or a positive stress 
test and angiographic diameter stenosis ≥50% by quantita-
tive coronary angiographic analysis or 2) angiographic di-
ameter stenosis ≥70% by quantitative coronary angiograph-
ic analysis without ischemic symptoms or a positive stress 
test. All clinical events were independently monitored and 
assessed by a Clinical Event Committee. 
Statistical analysis
Continuous variables are expressed as mean±standard devi-
Table 1. Baseline Clinical Characteristics 
Variables Full DES coverage (n=1200) Spot DES implantation (n=419) p value
Age (yrs) 61.8±9.7 62.9±9.6 0.055
Male sex (%) 758 (63.2) 247 (58.9) 0.126
Dyslipidemia (%) 716 (59.7) 242 (57.8) 0.493
Current smoker (%) 279 (23.3)   96 (22.9) 0.713
Hypertension (%) 725 (60.4) 274 (65.4) 0.071
Diabetes mellitus (%) 313 (26.1) 121 (28.9) 0.266
Previous myocardial infarction (%) 25 (2.1)   4 (1.0) 0.134
Previous PCI (%) 45 (3.8) 11 (2.6) 0.278
No. of diseased vessels (%) 0.115
    One 847 (70.6) 297 (70.9)
    Two 258 (21.5)   77 (18.4)
    Three 95 (7.9)   45 (10.7)
Ejection fraction (%) 64.34±8.95 64.52±9.44 0.743
Clinical presentation (%) 0.311
    Stable angina 541 (45.1) 172 (41.1)
    Unstable angina 502 (41.8) 184 (43.9)
    Acute myocardial infarction 157 (13.1)   63 (15.0)
PCI, percutaneous coronary intervention; DES, drug-eluting stent.
Values are presented as n (%) or mean±standard deviation. 
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risk for TVF to be almost 58% lower in patients subjected 
to spot DES implantation compared to those subjected to 
full DES coverage (HR=0.42, 95% CI=0.18-0.99, p=0.048) 
(Fig. 2). Subgroup analysis showed that the beneficial ef-
fects of spot DES implantation appeared to be more promi-
nent in the elderly and those with hypertension (Fig. 2). 
DISCUSSION
This study shows a lower rate of 1-year TVF in long lesions 
as well as other lesions in patients treated with a spot DES 
implantation compared with those treated with a full length 
DES. Lesion length was similar between the two groups. 
Therefore, we propose that efforts to minimize the implant-
ed stent length and the number of stents with overlapping 
during PCI procedures should be made regardless of lesion 
length. 
In the era of bare-metal stent, longer stent length was 
found to be an independent factor predicting restenosis, and 
multiple or physically longer stent implantations have been 
associated with an increased risk of major adverse cardiac 
though the average lesion length was similar between the 
two groups (20.58±10.97 mm vs. 21.36±10.30 mm, respec-
tively; p=0.206). Pre-intervention minimal lumen diameter 
was significantly smaller in the spot DES implantation group 
(1.00±0.47 mm vs. 1.09±0.48 mm, p=0.001), and the per-
cent diameter stenosis pre-PCI was significantly greater 
(67.38±14.35% vs. 64.54±14.31%, p=0.001).  
Clinical outcomes through 1-year follow-up are summa-
rized in Table 3. At 1 year, the rate of TVF was significantly 
lower in the spot DES implantation group (1.4% vs. 3.3%, 
p=0.044). Outcomes for the individual components of TVF 
at 1-year follow-up were similar between the two groups, 
except a lower rate of target vessel revascularization in the 
spot DES implantation group was observed (1.2% vs. 3.0%, 
p=0.043). A log-rank test revealed that the cumulative inci-
dence of TVF at 1-year was significantly lower in patients 
who underwent spot DES implantation than those subjected 
to full DES coverage (p=0.041) (Fig. 1). This association 
remained significant even after controlling for other risk 
factors including age, hypertension, lesion length, the DES 
type used, etc. (HR=0.40, 95% CI=0.17-0.98; p=0.046) 
(Table 4). The Cox proportional hazard model found the 
Table 2. Angiographic and Procedural Characteristics
Variables Full DES coverage (%) Spot DES implantation (%) p value
Treated artery 0.930
    Left anterior descending artery 731 (60.9) 259 (61.8)
    Right coronary artery 271 (22.6)   91 (21.7)
    Left circumflex artery 198 (16.5)   69 (16.5)
No. of stents   1.16±0.41 1.09±0.30 <0.001
Type of stents 0.253
    E-ZES 587 (48.9) 226 (53.9)
    Endeavor resolute 257 (21.4)   88 (21.0)
    Xience 127 (10.6) 35 (8.4)
    Cypher 229 (19.1)   70 (16.7)
Lesion length (mm)   20.58±10.97   21.36±10.30 0.206
Percent diameter stenosis (%)
    Pre-intervention   64.54±14.31   67.38±14.35 0.001
    Post-intervention 11.50±7.70 12.02±7.50 0.231
Reference diameter (mm)
    Pre-intervention   3.04±0.53   3.02±0.50 0.652
    Post-intervention   3.10±0.52   3.09±0.49 0.898
Minimal lumen diameter (mm)
    Pre-intervention   1.09±0.48   1.00±0.47 0.001
    Post-intervention   2.75±0.44   2.73±0.40 0.335
Use of intravascular ultrasound 556 (46.3) 205 (48.9) 0.360
Nominal stent length (mm)   25.44±13.24 23.14±9.70 <0.001
DES, drug-eluting stent; E-ZES, Endeavor zotarolimus-eluting stent.
Values are presented as n (%) or mean±standard deviation. 
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tively.18 Therefore, with the advent of the DES, the most 
considerable change in the implantation strategy is that lon-
ger or multiple DES implantations for full lesion coverage 
have usually been performed in an effort to minimize edge 
restenosis. 
However, a physically longer DES length was still asso-
ciated with poor clinical outcomes. The main problems of 
longer length of DES are associated with an increased risk 
of “hard” clinical outcomes (i.e., stent thrombosis) as well 
as “soft” clinical outcomes (i.e., restenosis).5-7 In addition, 
previous studies revealed that DES overlap was an inde-
pendent predictor of overall stent thrombosis and was asso-
ciated with impaired angiographic and long-term clinical 
outcome.19,20 Prolonged duration of DAPT would be associ-
ated with an increased risk of bleeding after longer DES 
implantation because of increased potential of stent throm-
bosis. Indeed, a large-scale multicenter registry study with 
301 patients with definite stent thrombosis (from 23500 
DES-treated patients) showed that longer stent length was 
one of the independent predictors of stent thrombosis.5 An-
other study with 3145 patients (4667 DES-treated lesions) 
showed that the threshold of stent length for predicting stent 
thrombosis was 31.5 mm; stent lengths greater than or equal 
to 31.5 mm were associated with higher rates of stent throm-
bosis at 3 years, compared with stent length less than 31.5 
mm (4.0% vs. 0.7%, respectively, p<0.001).6
The provisional spot stenting technique was initially pro-
events.11-13 However, previous studies have shown that treat-
ment of long coronary lesions by a DES significantly re-
duced the rates of restenosis and the need for target lesion 
revascularization compared with the use of bare-metal 
stent.14-17 An intravascular ultrasound study reported that the 
residual edge plaque burden was an independent predictor 
of angiographic edge restenosis after bare-metal and pacli-
taxel-eluting stent implantation; the cutoff value of the re-
sidual edge plaque burden was 47.7% and 47.1%, respec-
Table 3. Clinical Outcomes of Through 1 Year 
Variables Full DES coverage (%) Spot DES implantation (%) p value 
Composite events
    Target-vessel failure 40 (3.3) 6 (1.4) 0.044
    Death from any cause, myocardial infarction, 
      or stent thrombosis
10 (0.8) 3 (0.7) 0.999
    Death from cardiovascular cause or 
      myocardial infarction
  7 (0.6) 1 (0.2) 0.688
Individual components
    Death
        From any cause   6 (0.5) 2 (0.5) 0.999
        From cardiovascular cause   4 (0.3) 0 (0.0) 0.578
    Myocardial infarction   4 (0.3) 1 (0.2) 0.999
    Target-vessel revascularization 36 (3.0) 5 (1.2) 0.043
    Non-target vessel revascularization 14 (1.2) 7 (1.7) 0.432
    Stent thrombosis, definite or probable   5 (0.4) 0 (0.0) 0.336
    Bleeding
        Major or minor   7 (0.6) 3 (0.7) 0.725
        Major   3 (0.3) 1 (0.2) 0.999
    Cerebrovascular accidents   7 (0.6) 2 (0.5) 0.999
DES, drug-eluting stent.
Values are presented as n (%).
Fig. 1. Cumulative incidence of target vessel failure at 1 year. One year 
time-to-event curves are shown for target vessel failure in patients treated 
with full DES coverage versus spot DES implantation. Event rates represent 
Kaplan-Meier estimates. The p values are based on the log-rank test. CI, 
confidence interval; DES, drug-eluting stent.
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In the DES era, data on the spot DES implantation are scarce. 
One randomized study investigating the treatment of long 
coronary lesions with DESs showed that the 3-year major 
adverse cardiac event rate was significantly lower in the spot 
DES implantation group (n=89 patients) compared to the 
full DES coverage group (n=90 patients) (7.8% vs. 20%, re-
posed by Colombo, et al.8 and performed to minimize stent-
ed length for treatment of long coronary lesions in the era 
of the bare-metal stent. The target lesion revascularization 
rate was significantly lower in the provisional spot stenting 
group (n=130 lesions) compared with the traditional stenting 
group (n=143 lesions) (19% vs. 34%, respectively, p<0.05).8 
Table 4. Independent Predictors of 1-Year Target Vessel Failure in Cox’s Regression Analysis 
Predictors Hazard ratio (95% CI) p value 
Age (yrs) 1.01 (0.98-1.04) 0.678
History of hypertension 1.10 (0.60-2.02) 0.762
History of prior myocardial infarction 1.25 (0.17-9.19) 0.827
No. of diseased coronary arteries 0.90 (0.57-1.43) 0.652
No. of stents 1.61 (0.51-5.03) 0.416
E-ZES (vs. other DESs) 1.27 (0.71-2.28) 0.421
Pre-intervention MLD (mm) 0.65 (0.35-1.21) 0.170
Lesion length (mm) 1.02 (0.96-1.10) 0.507
Nominal stent length (mm) 0.99 (0.92-1.07) 0.822
Spot DES implantation (vs. full DES coverage) 0.40 (0.17-0.98) 0.046
CI, confidence interval; DES, drug-eluting stent; E-ZES, Endeavor-zotarolimus-eluting stent; MLD, minimal lumen diameter.
Values are presented as n (%) or mean±SD. 
Fig. 2. Subgroup analyses of the 1-year rates of target vessel failure. Subgroup analyses are shown for the target vessel failure at 1 year among subgroups 
of patients treated with full DES coverage versus spot DES implantation. The p value for interaction represents the likelihood of interaction between the vari-
able and the relative treatment effect. CI, confidence interval; DES, drug-eluting stent; E-ZES, Endeavor zotarolimus-eluting stent; MI, myocardial infarction; 
MLD, minimal lumen diameter.
Subgroup Target vessel failure Hazard ratio (95% CI)
p value for 
interaction
Spot DES 
implantation
Full DES 
coverage
Spot DES implantation 
Better
Full DES coverage 
Better
no./total (%)
Overall 6/419 (1.4) 40/1200 (3.3) 0.42 (0.18-0.99) 0.048
Age
    <65 yr 5/224 (0.5)   20/691 (2.9) 0.76 (0.29-2.03)
0.114
    ≥65 yr 1/195 (0.5)   20/509 (3.9) 0.13 (0.02-0.94)
Hypertension
    Yes 3/274 (1.1)   26/725 (3.6) 0.30 (0.09-0.99)
0.344
    No 3/145 (2.1)   14/475 (2.9) 0.69 (0.20-2.39)
Prior MI
    Yes 0/4 (0)        1/25 (4.0) 0.04 (0.00-1.90)
0.976
    No 6/415 (1.4) 39/1175 (3.3) 0.43 (0.18-1.01)
No. of stent
    1 5/383 (1.3) 28/1023 (2.7) 0.47 (0.18-1.21)
0.895
    ≥2   1/36 (2.8)   12/177 (6.8) 0.40 (0.05-3.08)
Stent type
    E-ZES 3/226 (1.3)   22/587 (3.7) 0.34 (0.10-1.15)
0.634
    Other DESs 3/193 (1.6)   18/613 (2.9) 0.52 (0.15-1.77)
Pre-intervention MLD
    <Median (1.05 mm) 5/221 (2.3)   23/582 (4.0) 0.55 (0.21-1.45)
0.328
    ≥Median (1.05 mm) 1/198 (0.5)   17/618 (2.8) 0.18 (0.02-1.36)
Lesion length
    <20 mm 2/225 (0.9)   19/754 (2.5) 0.35 (0.08-1.49)
0.818
    ≥20 mm 4/194 (2.1)   21/446 (4.7) 0.43 (0.15-1.24)
Nominal stent length
    <28 mm 4/315 (1.3)   23/835 (2.8) 0.45 (0.16-1.31)
0.889
    ≥28 mm 2/104 (1.9)   17/365 (4.7) 0.40 (0.09-1.72)
0.0
Difference (95% CI)
0.5 1.0 1.5 2.0 3.02.5
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number of patients in the spot DES implantation group.
In conclusion, minimizing the stent length and the num-
ber of stents with overlapping by spot DES implantation 
should be considered in the treatment of all lesions regard-
less of lesion length.  
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